Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 5:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 72 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Waldenstrom's Macroglobulinemia Clear all
Terminated Phase 2 Interventional Results available

Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia

NCT03679624
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia, Waldenstrom's Disease, Waldenström; Hypergammaglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia of Lymph Nodes, Waldenstrom's Macroglobulinaemia, Without Mention of Remission, Waldenstrom's Macroglobulinemia Refractory
Interventions
Ibrutinib, Daratumumab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 8, 2026, 5:46 PM EDT
Completed Phase 2 Interventional

Sildenafil Citrate in Waldenstrom's Macroglobulinemia

NCT00165295
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Sildenafil citrate (Viagra)
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 8, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

NCT00422656
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Perifosine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 8, 2026, 5:46 PM EDT
Completed Phase 2 Interventional

Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia

NCT00045695
View directory record Official record
Conditions
Lymphoma
Interventions
bortezomib
Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
2
States / cities
Hinsdale, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2013 · Synced Oct 8, 2026, 5:46 PM EDT
Not listed Phase 1Phase 2 Interventional

Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia

NCT00041379
View directory record Official record
Conditions
Lymphoma
Interventions
beta alethine
Drug
Lead sponsor
LifeTime Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 8, 2026, 5:46 PM EDT
Terminated Phase 2 Interventional Results available

Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia

NCT02439138
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
GS-1101
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 8, 2026, 5:46 PM EDT
Completed Phase 1 Interventional

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

NCT02071888
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Macroglobulinemia (WM), Other B-cell NHL Subtypes, Including WM, T-cell NHL
Interventions
CB-839, CB-839 and low dose dexamethasone, CB-839, pomalidomide, and low dose dexamethasone
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
Scottsdale, Arizona • Denver, Colorado • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 8, 2026, 5:46 PM EDT
Completed No phase listed Observational

S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.

NCT00919139
View directory record Official record
Conditions
Multiple Myeloma, Smoldering Myeloma, Waldenstrom's Macroglobulinemia, Monoclonal Gammopathy of Undetermined Significance, Amyloidosis
Interventions
biologic sample preservation procedure
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
207
States / cities
Little Rock, Arkansas • Berkeley, California • Burlingame, California + 141 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 8, 2026, 5:46 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

NCT00492050
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Bortezomib, Rituximab, Valacyclovir
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 8, 2026, 5:46 PM EDT
Terminated Phase 2 Interventional Results available

CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia

NCT00142168
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
CC-5103 (lenalidomide), Rituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Oct 8, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia

NCT01470196
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Dexamethasone, Carfilzomib, Rituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 8, 2026, 5:46 PM EDT
Completed Phase 1 Interventional

Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab

NCT00667329
View directory record Official record
Conditions
Lymphoma
Interventions
2CdA, Cyclophosphamide, Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 8, 2026, 5:46 PM EDT
Terminated Phase 2 Interventional Results available

DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients

NCT00107614
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia
Interventions
DT PACE + Rituxan
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2011 · Synced Oct 8, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma

NCT00718419
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia, Multiple Myeloma
Interventions
Enzastaurin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 8, 2026, 5:46 PM EDT
Completed Phase 1 Interventional

Carfilzomib Plus Belinostat in Relapsed/Refractory NHL

NCT02142530
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Peripheral T-cell Lymphoma
Interventions
Carfilzomib, Belinostat
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Oct 8, 2026, 5:46 PM EDT
Completed Phase 2 Interventional

A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma

NCT00081809
View directory record Official record
Conditions
Lymphoma, Follicular, Lymphoma, Small Lymphocytic
Interventions
autologous human tumor-derived HSPPC-96
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 8, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients

NCT02566265
View directory record Official record
Conditions
Influenza, Multiple Myeloma, Waldenstrom's Macroglobulinemia, Plasma Cell Disorders, MGUS
Interventions
Fluzone High Dose Vaccine, Standard of care/Placebo
Biological
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 8, 2026, 5:46 PM EDT
Completed Phase 1Phase 2 Interventional

Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia

NCT00004107
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 epratuzumab
Biological · Procedure · Radiation
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
4
States / cities
Belleville, New Jersey • Livingston, New Jersey • Paterson, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 8, 2026, 5:46 PM EDT
Completed Phase 1 Interventional

A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

NCT00807677
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma, Waldenstrom's Macroglobulinemia, Myelodysplastic Syndrome, Philadelphia Chromosome-negative CML, Myeloid Metaplasia, Myelofibrosis, Advanced Polycythemia, Non-Hodgkins Lymphoma
Interventions
TAK-901
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Oct 8, 2026, 5:46 PM EDT
Completed Not applicable Interventional

Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia

NCT00142155
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Rituximab, monoclonal antibodies
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
30 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 8, 2026, 5:46 PM EDT
Terminated Phase 2 Interventional Results available

Simvastatin in Waldenstrom's Macroglobulinemia

NCT00575965
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Simvastatin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Oct 8, 2026, 5:46 PM EDT
Completed Phase 2 Interventional

Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia

NCT00020800
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, fludarabine phosphate
Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
14
States / cities
Tucson, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Oct 8, 2026, 5:46 PM EDT
Terminated Phase 1 Interventional

Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma

NCT00671112
View directory record Official record
Conditions
714leukemia, Lymphoma
Interventions
Bortezomib, Everolimus
Drug
Lead sponsor
Brian Hill, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 8, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia

NCT00936611
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
LBH589
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Denver, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 8, 2026, 5:46 PM EDT